Dr. Salgia on Importance of Molecular Markers in Lung Cancer

Video

In Partnership With:

Ravi Salgia, MD, PhD, Arthur & Rosalie Kaplan Chair in Medical Oncology, associate director for clinical sciences at City of Hope, discusses the importance of molecular markers in lung cancer.

Ravi Salgia, MD, PhD, Arthur & Rosalie Kaplan Chair in Medical Oncology, associate director for clinical sciences at City of Hope, discusses the importance of molecular markers in lung cancer.

Lung cancer can be subdivided into histology subtypes, like non-small cell lung cancer (NSCLC) and small cell lung cancer. There are also adenocarcinomas, nonsquamous cell carcinomas, squamous cell carcinomas, and sometimes large cell carcinomas, but there are also subsets in terms of molecular markers, Salgia adds. There are EGFR mutations, ALK translocations, or ROS1 translocations, which can be discovered through a molecular test.

Salgia says that molecular testing is imperative and standard. Molecular testing can indicate a targetable pathway for a patient, and can open up additional treatment options if the patient harbors a particular mutation. As a standard practice in NSCLC, molecular testing has transformed therapeutic approaches and sequencing for patients.

Related Videos
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine